A pH-responsive silica–metal–organic framework hybrid nanoparticle for the delivery of hydrophilic drugs, nucleic acids, and CRISPR-Cas9 genome-editing machineries
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Efficient delivery of hydrophilic drugs, nucleic acids, proteins, and any combination thereof is essential for various biomedical applications. Herein, we report a straightforward, yet versatile approach to efficiently encapsulate and deliver various hydrophilic payloads using a pH-responsive silica–metal–organic framework hybrid nanoparticle (SMOF NP) consisting of both silica and zeolitic imidazole framework (ZIF). This unique SMOF NP offers a high loading content and efficiency, excellent stability, and robust intracellular delivery of a variety of payloads, including hydrophilic small molecule drugs (e.g., doxorubicin hydrochloride), nucleic acids (e.g., DNA and mRNA), and genome-editing machineries (e.g., Cas9-sgRNA ribonucleoprotein (RNP), and RNP together with donor DNA (e.g., RNP+ssODN)). The superior drug delivery/gene transfection/genome-editing efficiencies of the SMOF NP are attributed to its pH-controlled release and endosomal escape capabilities due to the proton sponge effect enabled by the imidazole moieties in the SMOF NPs. Moreover, the surface of the SMOF NP can be easily customized (e.g., PEGylation and ligand conjugation) via various functional groups incorporated into the silica component. RNP-loaded SMOF NPs induced efficient genome editing in vivo in murine retinal pigment epithelium (RPE) tissue via subretinal injection, providing a highly promising nanoplatform for the delivery of a wide range of hydrophilic payloads.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062 · cited 1×
“After the double-stranded DNA break is generated, gene deletion can be achieved by the nonhomologous end-joining (NHEJ) DNA repair pathway[30, 31].”
BackgroundPrinciples of nanoparticle design for overcoming biological barriers to drug delivery
Blanco, E., Shen, H., & Ferrari, M. (2015) · Nature Biotechnology · doi:10.1038/nbt.3330 · Cited by 7,002
A robust and high-throughput Cre reporting and characterization system for the whole mouse brain
Madisen, L., Zwingman, T. A., Sunkin, S. M., Oh, S. W., Zariwala, H. A., Gu, H., Ng, L. L., Palmiter, R. D., Hawrylycz, M. J., Jones, A. R., et al. (2010) · Nature Neuroscience · doi:10.1038/nn.2467 · Cited by 6,907
Non-viral vectors for gene-based therapy
Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123
Richardson, C. D., Ray, G. J., DeWitt, M. A., Curie, G. L., & Corn, J. E. (2016) · Nature Biotechnology · doi:10.1038/nbt.3481 · Cited by 1,098
Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications
Liu, C., Zhang, L., Liu, H., & Cheng, K. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.012 · Cited by 607
Alsaiari, S. K., Patil, S., Alyami, M., Alamoudi, K. O., Aleisa, F. A., Merzaban, J. S., Li, M., & Khashab, N. M. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.7b11754 · Cited by 517 · cited 2×
“Moreover, the excellent pHbuffering capacity of the imidazole bridging ligand confers pH-responsive capabilities to the ZIF, as well as an enhanced ability to escape the endocytic pathway[18].”
BackgroundStaahl, B. T., Benekareddy, M., Coulon-Bainier, C., Banfal, A. A., Floor, S. N., Sabo, J. K., Urnes, C., Munares, G. A., Ghosh, A., & Doudna, J. A. (2017) · Nature Biotechnology · doi:10.1038/nbt.3806 · Cited by 355
Jacobson, S. G., Acland, G. M., Aguirre, G. D., Aleman, T. S., Schwartz, S. B., Cideciyan, A. V., Zeiss, C. J., Komaromy, A. M., Kaushal, S., Roman, A. J., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.03.005 · Cited by 224
Protein delivery into cells using inorganic nanoparticle–protein supramolecular assemblies
Scaletti, F., Hardie, J., Lee, Y.-W., Luther, D. C., Ray, M., & Rotello, V. M. (2018) · Chemical Society Reviews · doi:10.1039/c8cs00008e · Cited by 208
Cited by
Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR/Cas9 genome editing
Zhang, S., Shen, J., Li, D., & Cheng, Y. (2021) · Theranostics · doi:10.7150/thno.47007 · Cited by 430
Recent advances in exosome-mediated nucleic acid delivery for cancer therapy
Zhang, Y., Liu, Q., Zhang, X., Huang, H., Tang, S., Chai, Y., Xu, Z., Li, M., Chen, X., Liu, J., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01472-z · Cited by 306
Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment
Xu, X., Liu, C., Wang, Y., Koivisto, O., Zhou, J., Shu, Y., & Zhang, H. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113891 · Cited by 289
Self-citationIn vivo delivery of CRISPR-Cas9 therapeutics: Progress and challenges
Behr, M., Zhou, J., Xu, B., & Zhang, H. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.05.020 · Cited by 210
Self-citationSalman, A., Kantor, A., McClements, M. E., Marfany, G., Trigueros, S., & MacLaren, R. E. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091842 · Cited by 37
Metadata
- Authors
- Wang, Y., Shahi, P. K., Xie, R., Zhang, H., Abdeen, A. A., Yodsanit, N., Ma, Z., Saha, K., Pattnaik, B. R., & Gong, S.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2020-08
- Volume
- 324
- Pages
- 194-203
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W3021692086
- Cited by
- 107
- References
- 12
- FWCI
- 3.29
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A pH-responsive silica–metal–organic framework hybrid nanoparticle for the delivery of hydrophilic drugs, nucleic acids, and CRISPR-Cas9 genome-editing machineries. https://app.cochat.ai/papers/10.1016/j.jconrel.2020.04.052
- The paper
- Wang, Y., Shahi, P. K., Xie, R., Zhang, H., Abdeen, A. A., Yodsanit, N., Ma, Z., Saha, K., Pattnaik, B. R., & Gong, S. (2020). A pH-responsive silica–metal–organic framework hybrid nanoparticle for the delivery of hydrophilic drugs, nucleic acids, and CRISPR-Cas9 genome-editing machineries. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2020.04.052
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.